Thalidomide

Known as: N-Phthalyl-glutaminsaeure-imid, 2,6-Dioxo-3-phthalimidopiperidine, (+-)-Thalidomide 
A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic… (More)
National Institutes of Health

Related topics

Related topics

43 relations

Narrower (17)

3'-methylthalidomide3-aminophthalimidoglutarimide5'-hydroxythalidomideCC-885
(More)

Broader (5)

AminesAnalgesicsLeprostatic AgentsPiperidones
(More)
Angiogenesis InhibitionAphthous StomatitisEndothelial CellsErythema Multiforme
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Identification of a primary target of thalidomide teratogenicity.
Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology…
PURPOSE To determine if thalidomide plus dexamethasone yields superior response rates compared with dexamethasone alone as… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Newer chemotherapeutic protocols as well as high-dose chemotherapy have increased the response rate in myeloma. However, these… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
The antiangiogenic activity of thalidomide (Thal), coupled with an increase in bone marrow angiogenesis in multiple myeloma (MM… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Although thalidomide (Thal) was initially used to treat multiple myeloma (MM) because of its known antiangiogenic effects, the… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Antitumor activity of thalidomide in refractory multiple myeloma.
BACKGROUND Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Thalidomide is an inhibitor of angiogenesis.
Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered… (More)
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
We have examined the mechanism of thalidomide inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
1991
Highly Cited
1991
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1961
Highly Cited
1961
THALIDOMIDE AND CONGENITAL ABNORMALITIES
determined for each state in the nation. For the first time in many areas, hospital licensure laws were created and implemented… (More)
Is this relevant?